The company will officially open the new US subsidiary on 15 September with a ribbon cutting ceremony at 11 am
South Korean-based GPCR Therapeutics has announced that to accommodate the expansion of its US subsidiary, it has relocated from incubator space in San Carlos. GPCR’s US operations will be based in a new office and laboratory space at 400 Seaport Court, Redwood City.
GPCR Therapeutics is a venture-backed clinical stage international biopharmaceutical company with an approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pair.
Dr Dong Seung Seen, GPCR’s founder and CEO, said: “We are delighted to be growing in one of the world’s biggest and best biotech clusters, as neighbours to pharma companies including AbbVie and Bristol Myers Squibb, and many other innovation-driven biotech companies.”
GPCR’s President of US operations, Dr Pina Cardarelli, said, “We believe our science will lead to the discovery of specific combination drugs that are more efficacious for cancer treatment, thereby leading to better patient outcomes.”
We will be proud to launch our first human clinical trials, resulting from outstanding work done over many years by our exceptional teams in South Korea and the USA
The new US location has over 8,000 square feet covering one floor, dedicated to GPCR’s R&D efforts and will accommodate capabilities in cell culture, protein engineering, computational chemistry, and high-throughput screening. In addition, GPCR’s new site has ample room for growth, as the current team of 10 employees is expected to nearly double over the coming year.
As GPCR expands, it is actively expanding its scientific teams to scale up its R&D programs and start clinical trials.
“We will be proud to launch our first human clinical trials, resulting from outstanding work done over many years by our exceptional teams in South Korea and the USA,” concluded Dr Seen.
GPCR Therapeutics has recently become a member of the San Mateo County Chamber of Commerce.